OncoMatch/Clinical Trials/NCT04727307
Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
Is NCT04727307 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Atezolizumab (neoadjuvant) and Bevacizumab (adjuvant) for hepatocellular carcinoma.
Treatment: Atezolizumab (neoadjuvant) · Bevacizumab (adjuvant) · Atezolizumab (adjuvant) — Following the results of study IMbrave150, the combination Atezolizumab + Bevacizumab is a promising treatment option for patients with HCC. In addition, the high intrahepatic distant recurrence rate and accumulating evidence for a metastatic mechanism encourages exploring adjuvant/neoadjuvant strategies targeting tumor growth and metastatic escape in the context of percutaneous thermal ablation for small HCC. Local ablation of HCC is therefore an "ideal" setting for testing atezolizumab + bevacizumab in combination with ablation, with the aim of reducing the risk of recurrence.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: liver transplantation
Prior liver transplantation
Cannot have received: chemo-embolization
Prior chemo-embolization
Cannot have received: radio-embolization
Prior radio-embolization
Cannot have received: surgery of HCC with micro- or macro-vascular invasion
Prior surgery of HCC with micro- or macro-vascular invasion demonstrated at pathology
Cannot have received: systemic treatment for HCC
Prior systemic treatment for HCC, in particular agents targeting T-cell costimulation or checkpoint pathways (including those targeting PD-1, PD-L1 or PD-L2, cluster of differentiation 137 (CD137), or cytotoxic T-lymphocyte antigen (CTLA-4))
Lab requirements
Blood counts
Hemoglobin > 8.5 g/dL; Absolute neutrophil count ≥ 1500/mm3; Platelet count ≥ 50,000/ mm3; Prothrombin time > 50%
Kidney function
Serum creatinine ≤ 1.5 x ULN; Glomerular Filtration Rate (GFR) ≥ 35 mL/min/1.73 m2
Liver function
Total bilirubin ≤ 2 mg/dL (ou ≤ 34 µmol/ L). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x upper limit of normal (ULN)
Adequate bone marrow, liver and renal function as assessed by the following laboratory tests: Hemoglobin > 8.5 g/dL; Absolute neutrophil count ≥ 1500/mm3; Platelet count ≥ 50,000/ mm3; Total bilirubin ≤ 2 mg/dL (ou ≤ 34 µmol/ L). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x upper limit of normal (ULN); Serum creatinine ≤ 1.5 x ULN; Lipase ≤ 2 x ULN; Prothrombin time > 50%; Glomerular Filtration Rate (GFR) ≥ 35 mL/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04727307 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages